Former BioD investors are looking for an accelerated $26.5 million earnout after ex-CEO Russell Olsen resigned from Integra Lifesciences (NSDQ:IART). BioD merged with Derma Sciences for $80 million in Aug. 2016., which was later bought by Integra for $200 million. After the series of acquisition, Olsen told Integra that he believed his new job offer materially diminished […]
Derma Sciences Inc.
Integra LifeSciences closes $200m Derma Sciences buy
Integra LifeSciences (NSDQ:IART) said today that it closed its $205 million buy of Derma Sciences (NSDQ:DSCI) and its line of wound care products. The $7-per-share deal included a line of regenerative allograft products derived from human placental tissue that Derma Sciences acquired when it paid nearly $80 million for BioD last year. Integra also agreed to pay $32 per share […]
Derma Sciences pays $13m for Medihoney ahead of Integra buyout
Derma Sciences (NSDQ:DSCI) said last week that it paid $13.3 million for Medihoney, on the same day that Integra LifeSciences (NSDQ:IART) agreed to pay nearly $200 million for the tissue regeneration company. Prior to the acquisition, Derma Sciences held the exclusive global license for the Comvita-owned Medihoney brand and patents. Medihoney is eligible to receive an additional […]
Integra LifeSciences to acquire Derma Sciences for $200m
Integra LifeSciences (NSDQ:IART) said yesterday that it agreed to pay nearly $200 million for Derma Sciences (NSDQ:DSCI) and its line of wound care products. The $7-per-share deal includes a line of regenerative allograft products derived from human placental tissue that Derma Sciences acquired when it paid nearly $80 million for BioD last year. Integra also agreed to […]
Titan Medical loses clinical & regulatory EVP Fowler | Personnel Moves for August 29, 2016
Titan Medical loses clinical & regulatory EVP Fowler Titan Medical (CVE:TMD) said today that its executive vice president for clinical & regulatory affairs, Dr. Dennis Fowler, plans to resign effective August 31. Toronto-based robot-assisted surgery company Titan, which is grappling with the suspension of its product development program, said Fowler’s duties will be divided on an […]
Derma Sciences, Organogenesis tout Medicare reimbursement win
Updated to include more information, commentary from Organogenesis. Medicare administrative contractor National Government Services has retired previous coverage policies on cellular and tissue-based products, effective September 1st. The change will allow new coverages and reimbursement through Medicare for such products based on FDA labeling and packaging. Derma Sciences (NSDQ:DSCI and Organogenesis have said the changes will allow for their products […]
Derma Sciences closes $80m deal for BioD
Derma Sciences (NSDQ:DSCI) said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs. Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs […]
Derma Sciences acquires BioD for $21.3m
Derma Sciences (NSDQ:DSCI) said today it is buying regenerative medicine developer BioD for $21.3 million up front, with the possibility of an additional $56.5 million. The deal between Princeton, N.J.-based Derma Sciences and Cordova, Tenn.-based BioD includes regulatory milestone payments up to $30 million and earn outs based on net sales growth of up to $26.5 million. “The acquisition of […]
Avedro CEO Muller is out | Personnel Moves
Avedro said CEO David Muller stepped down shortly after it closed a $32 million equity round last month, replaced on an interim basis by COO Brian Roberts, the former CFO at Insulet (NSDQ:PODD). Waltham-based Avedro said Muller left to “pursue other opportunities.” “On behalf of the board and all the Avedro employees, I want to thank […]
Derma Sciences scraps trial, mulls sale
Derma Sciences (NSDQ:DSCI) said today it would evaluate all options, including a sale, after scrapping a trial of its aclerastide drug for diabetic foot ulcers. DSCI shares plunged as much as 31%, dropping under their 6-year low today. The company makes wound care and regenerative medicine products. Aclerastide was its only drug candidate. Princeton, N.J.-based Derma Sciences said […]
Derma Sciences losses widen, sales increase in Q3

Derma Sciences (NSDQ:DSCI) got a little bit of attention from Wall Street today, with shares up a modest 0.6% in late afternoon trading following release of the company’s Q3 earnings.